全文获取类型
收费全文 | 9176篇 |
免费 | 108篇 |
国内免费 | 1篇 |
专业分类
电工技术 | 139篇 |
综合类 | 4篇 |
化学工业 | 848篇 |
金属工艺 | 109篇 |
机械仪表 | 143篇 |
建筑科学 | 166篇 |
矿业工程 | 32篇 |
能源动力 | 104篇 |
轻工业 | 691篇 |
水利工程 | 42篇 |
石油天然气 | 22篇 |
无线电 | 793篇 |
一般工业技术 | 980篇 |
冶金工业 | 4387篇 |
原子能技术 | 109篇 |
自动化技术 | 716篇 |
出版年
2021年 | 47篇 |
2019年 | 45篇 |
2018年 | 51篇 |
2017年 | 56篇 |
2016年 | 73篇 |
2015年 | 51篇 |
2014年 | 82篇 |
2013年 | 183篇 |
2012年 | 164篇 |
2011年 | 228篇 |
2010年 | 194篇 |
2009年 | 208篇 |
2008年 | 227篇 |
2007年 | 232篇 |
2006年 | 199篇 |
2005年 | 202篇 |
2004年 | 185篇 |
2003年 | 165篇 |
2002年 | 142篇 |
2001年 | 148篇 |
2000年 | 163篇 |
1999年 | 238篇 |
1998年 | 1131篇 |
1997年 | 689篇 |
1996年 | 498篇 |
1995年 | 317篇 |
1994年 | 279篇 |
1993年 | 349篇 |
1992年 | 154篇 |
1991年 | 167篇 |
1990年 | 156篇 |
1989年 | 170篇 |
1988年 | 156篇 |
1987年 | 137篇 |
1986年 | 147篇 |
1985年 | 131篇 |
1984年 | 87篇 |
1983年 | 93篇 |
1982年 | 83篇 |
1981年 | 71篇 |
1980年 | 74篇 |
1979年 | 80篇 |
1978年 | 81篇 |
1977年 | 141篇 |
1976年 | 256篇 |
1975年 | 60篇 |
1974年 | 56篇 |
1973年 | 53篇 |
1972年 | 37篇 |
1971年 | 36篇 |
排序方式: 共有9285条查询结果,搜索用时 15 毫秒
1.
Margeaux A. Miller Prof. Dr. Ellen M. Sletten 《Chembiochem : a European journal of chemical biology》2020,21(24):3451-3462
Perfluorocarbons, saturated carbon chains in which all the hydrogen atoms are replaced with fluorine, form a separate phase from both organic and aqueous solutions. Though perfluorinated compounds are not found in living systems, they can be used to modify biomolecules to confer orthogonal behavior within natural systems, such as improved stability, engineered assembly, and cell-permeability. Perfluorinated groups also provide handles for purification, mass spectrometry, and 19F NMR studies in complex environments. Herein, we describe how the unique properties of perfluorocarbons have been employed to understand and manipulate biological systems. 相似文献
2.
摘 要:主要介绍Sasol Agri公司硫酸四系统的技术改造,分两步进行,第一步更换转化器、热换热器及主省煤器,生产能力由1600t/d提高到1750 t/d,且鼓风机出口压力很低。第二步更换干燥塔、二吸塔及冷换热器,连续生产能力在1950 t/d以上。使用不锈钢材质及克瓦纳·凯密迪公司专有的换热器,使装置的改造相当成功,维护及操作费用较低,并具有较大的灵活性和可操作性。 相似文献
3.
可重定位的基于事务的系统级验证 总被引:2,自引:0,他引:2
功能验证已经成为开发SoC的主要问题。随着一些复杂SoC的规模超过两千万门,以及对开发和集成嵌入式软件的需求持续增加,软件模拟器已经力所不及。在设计过程需要几百万个时钟周期来充分测试和验证软件功能的情况下,软件仿真器的性能下降到1-5Hz。按照这种速率,软件调试需要几年的时 相似文献
4.
5.
GA Masters AM Mauer PC Hoffman D Wyka BL Samuels SA Krauss S Watson H Golomb EE Vokes 《Canadian Metallurgical Quarterly》1998,9(6):677-680
PURPOSE: We designed a phase I-II trial of three active agents, paclitaxel, ifosfamide, and vinorelbine, in advanced non-small-cell lung cancer (NSCLC) to: 1) define the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of paclitaxel with filgrastim (G-CSF) support; and 2) determine the overall response rate and median survival of patients treated on this regimen. PATIENTS AND METHODS: We treated cohorts of patients with stage IIIB or IV NSCLC with ifosfamide 1.2-1.6 g/m2/day x 3 and vinorelbine 20-25 mg/m2/day x 3 and escalating doses of paclitaxel at 100-175 mg/m2 on day 2 with G-CSF support on a 21-day cycle. One prior experimental single-agent chemotherapy regimen was allowed. RESULTS: Fifty-six patients, were enrolled on this trial: 27 on the phase I portion of the study and an additional 29 at the recommended phase II dose (RPTD). Thirteen patients had received prior chemotherapy. Paclitaxel doses of 175 mg/m2 and 150 mg/m2 produced dose-limiting myelosuppression, and the RPTD was determined to be paclitaxel 135 mg/m2 with ifosfamide 1.2 g/m2/day on days 1-3 and vinorelbine 20 mg/m2/ day on days 1-3 with G-CSF support. The overall response rate was 18%, with a median survival of 6.1 months. Six of 35 patients (17%) treated at the RPTD achieved a partial response to therapy. Grade IV neutropenia was observed in 19 of 35 patients at this dose, with eight patients suffering febrile neutropenia. CONCLUSIONS: This non-cisplatin-containing three-drug regimen has substantial toxicity and low activity in advanced NSCLC, and does not seem to improve on prior regimens. It is unclear whether the lack of efficacy relates to an antagonistic reaction between the specific drugs, administration schedule, or to subtherapeutic doses of the individual agents. 相似文献
6.
7.
FJ Overdyk PM Gramling-Babb JR Handy NI Faller MJ Miller 《Canadian Metallurgical Quarterly》1997,84(1):213-215
Robertsonian translocations, although relatively common as a constitutional genetic aberration, are rarely encountered in leukaemia. We report a case of acute myeloid leukaemia which showed an acquired Robertsonian translocation in the form of der(14;21) by cytogenetic analysis of leukaemic cells. This was confirmed by the PHA-stimulated culture of peripheral blood lymphocytes. A review of the literature identifies only eight reported cases of acquired Robertsonian translocations in leukaemia. In the majority of cases the Robertsonian translocation occurs as a secondary change in a complex abnormal clone, whereas in two out of nine patients reported, including ours, it is found as a sole karyotypic abnormality. 相似文献
8.
9.
RM Campbell EP Heimer M Ahmad HG Eisenbeis TJ Lambros Y Lee RW Miller PR Stricker AM Felix 《Canadian Metallurgical Quarterly》1997,49(6):527-537
In the present study, human growth hormone-releasing factor (hGRF) and analogs were successfully pegylated at the carboxy-terminus using a novel solid- and solution-phase strategy. Following synthesis, these pegylated hGRF analogs were evaluated for in vitro and in vivo biological activity. Specifically, hGRF (1-29)-NH2, [Ala15]-hGRF (1-29)-NH2, [desNH2Tyr1, D-Ala2, Ala15]-hGRF(1-29)-NH2 and [His1, Val2, Gln8, Ala15, Leu27]-hGRF(1-32)-OH were each C-terminally extended using a Gly-Gly-Cys-NH2 spacer (previously demonstrated not to alter intrinsic biological activity), and then monopegylated via coupling to an activated dithiopyridyl-PEG reagent. PEG moieties of 750, 2000, 5000 or 10,000 molecular weight (MW) were examined to determine the effect of polymer weight on activity. Initial biological evaluations in vitro revealed that all C-terminally pegylated hGRF analogs retained high growth hormone (GH)-releasing potencies, regardless of the MW of PEG polymer employed. Two of these pegylated hGRF analogs, [desNH2Tyr1, D-Ala2, Ala15]-hGRF (1-29)-Gly-Gly-Cys(NH2)-S-Nle-PEG5000 and [His1, Val2, Gln8, Ala15, Leu27]-hGRF(1-32)-Gly-Cys(NH2)-S-Nle-PEG5000, were subsequently evaluated in both pig and mouse models and found to be highly potent (in vivo potency range = 12-55-fold that of native hGRF). Relative to their non-pegylated counterparts, these two pegylated hGRF analogs exhibited enhanced duration of activity. 相似文献
10.
CL Mesh BL Cmolik DW Van Heekeren JH Lee D Whittlesey LM Graham AS Geha SJ Bowlin 《Canadian Metallurgical Quarterly》1997,11(6):612-619
A premise of cardiac risk stratification is that the added risk of coronary artery bypass grafting (CABG) is offset by the improved safety of subsequent vascular reconstruction (VR). We questioned if elective CABG is patients with severe peripheral vascular disease (PVD) is a relatively high-risk procedure. A cohort study of 680 elective CABG patients from January 1993 to December 1994 was performed using three mutually exclusive outcomes of complication-free survival, morbidity, and mortality. Patient characteristic, operative, and outcome data were prospectively collected. Retrospective review determined that 58 patients had either a standard indication for or a history of VR. Overall CABG mortality was 2.5%, with statistically similar but relatively higher rates for PVD as compared to non-PVD patients. In contrast, major morbidity occurred at rates 3.6-fold higher in PVD patients (39.7%) than in disease-free patients (16.7%) after adjustment for the effects of patient and operative variables (odds ratio [OR] 3.67, 95% confidence interval [CI] 1.93-6.99). CABG morbidity in the PVD patient was most likely in those patients with aortoiliac (OR 9.51, CI 3.20-28.27) and aortic aneurysmal (OR 5.24, CI 1.28-21.41) disease types. CABG in PVD patients is associated with significant major morbidity. Such morbidity may preclude or alter the timing of subsequent VR. 相似文献